How should a reported penicillin allergy be evaluated and worked up?

Penicillin Allergy Workup

For patients reporting a penicillin allergy, begin with a detailed clinical history focused on the characteristics of the index reaction, then proceed with risk stratification to determine whether direct delabeling, drug challenge testing, or formal allergy testing is appropriate 1, 2.

Initial Clinical Assessment

The cornerstone of evaluation is obtaining specific details about the index reaction 1:

Critical historical elements to document:

• Exact symptoms (urticaria, angioedema, anaphylaxis, rash type, gastrointestinal symptoms)
• Timing of reaction relative to drug administration (immediate <1 hour, accelerated 1-72 hours, delayed >72 hours) 3
• Time elapsed since the index reaction occurred
• Severity of the reaction (mild cutaneous vs. systemic involvement)
• Setting where reaction was observed (witnessed by healthcare personnel vs. patient-reported)
• Specific penicillin involved (if known)
• Age at time of reaction

Risk Stratification Framework

Low-Risk Patients (Direct Delabeling Appropriate)

These patients can have their allergy label removed based on history alone or proceed directly to drug challenge 3, 1, 4:

• Isolated non-allergic symptoms (nausea, headache, fatigue, gastrointestinal upset)
• Family history only without personal reaction
• Pruritus alone without rash
• Remote reaction (>10 years ago) with unknown/vague details and no features of IgE-mediated reaction
• Clearly non-immunologic reactions

For low-risk patients, direct amoxicillin challenge without prior testing is appropriate 4. The combination of absent anaphylaxis, unknown drug name, and reaction >1 year prior has a 98.4% negative predictive value for true IgE-mediated allergy 1.

Moderate-Risk Patients (Consider Testing Before Challenge)

• Urticaria or pruritic rashes
• Reactions with some features suggesting IgE-mediated mechanism
• Cutaneous-only reactions occurring 1-10 years ago
• Maculopapular exanthema

High-Risk Patients (Formal Allergy Evaluation Required)

• Anaphylaxis (respiratory compromise, hypotension, multi-system involvement) 1
• Severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS)
• Angioedema
• Serum sickness-like reactions
• Recent reaction (<1 year) with systemic involvement 1
• Reaction observed and documented by healthcare personnel 1
• Multiple β-lactam reactions
• Previous positive penicillin skin testing

Diagnostic Testing Approach

Penicillin Skin Testing (PST)

Important caveat: Skin testing has limited sensitivity (30.7%) but high specificity (96.8%) 5. This means:

• A negative skin test does NOT rule out allergy and must be followed by drug challenge
• A positive skin test strongly suggests true allergy
• Skin testing alone is insufficient for delabeling 5

PST detects IgE antibodies against penicillin determinants and should include both major (penicilloyl-polylysine) and minor determinants (benzylpenicillin) 3.

Specific IgE Testing

Even more limited utility than skin testing, with sensitivity of only 19.3% and specificity of 97.4% 5. Should only be performed in adult patients with immediate reactions (<2 hours) or urticaria 6. Not recommended as a standalone test.

Drug Challenge/Provocation Testing

This is the gold standard for confirming or excluding penicillin allergy 3, 1.

Key evidence on safety:

• In low-risk patients undergoing direct challenge (without prior skin testing), 94% tolerated the challenge successfully 1
• Reactions during challenge are typically mild and manageable with antihistamines 3
• Serious reactions requiring epinephrine are rare, occurring in <1% of challenges 3

Challenge protocol:

• Graded dosing starting with very low dose, escalating under medical supervision 3
• Must be performed in setting equipped to manage anaphylaxis 3
• For negative skin test patients, challenge confirms tolerance in >95-100% of cases 4

Clinical Context: Why This Matters

Over 90% of patients labeled with penicillin allergy are not truly allergic 3, 1, 7. The prevalence of reported penicillin allergy varies globally (2% in Hong Kong to 12% in Belgium), but less than 5% of labeled patients have confirmed allergy with appropriate testing 3.

Critical pitfalls to avoid:

• IgE-mediated penicillin allergy wanes over time, with 80% of patients becoming tolerant after 10 years 4
• Cross-reactivity between penicillin and cephalosporins occurs in only ~2% of cases, not the previously reported 8% 4
• Children have lower risk of true allergy than adults, though severe reactions in children are more likely to represent true allergy 1
• Aminopenicillins account for >70% of reported reactions, likely because they are most frequently prescribed 1

Consequences of Inappropriate Avoidance

Patients with unverified penicillin allergy labels who receive alternative antibiotics face 4, 7:

• Increased antimicrobial resistance (MRSA, VRE)
• Higher rates of Clostridioides difficile infection
• Longer hospital stays
• More readmissions
• Higher healthcare costs
• Increased drug toxicity from broader-spectrum agents

Practical Algorithm

1. Obtain detailed history of index reaction with specific focus on timing, symptoms, severity, and time elapsed
2. Classify risk level based on history
3. Low-risk: Direct delabeling or direct amoxicillin challenge
4. Moderate-risk: Consider skin testing followed by challenge if negative, OR direct challenge in appropriate clinical setting
5. High-risk: Refer to allergy specialist for formal evaluation; avoid β-lactams until evaluated
6. Non-immunologic reactions: Remove label immediately

For patients requiring urgent β-lactam therapy with unclear history, a risk-stratified approach should enable most patients to receive appropriate treatment, with formal testing deferred until after acute management 8.